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original work is propObjective: To assess associations between engagement in-care and future mortality.
Design: UK-based observational cohort study.
Methods: HIV-positive participants with more than one visit after 1 January 2000 were
identified. Each person-month was classified as being in or out-of-care based on the
dates of the expected and observed next care visits. Cox models investigated associ-
ations between mortality and the cumulative proportion of months spent in-care (% IC,
lagged by 1 year), and cumulative %IC prior to antiretroviral therapy (ART) in those
attending clinic for more than 1 year, with adjustment for age, CD4þ/viral load, year,
sex, infection mode, ethnicity, and receipt/type of ART.
Results: The 44432 individuals (27.8% women; 50.5% homosexual, 28.9% black
African; median age 36 years) were followed for a median of 5.5 years, over which time
2279 (5.1%) people died. Higher %IC was associated with lower mortality both before
[relative hazard 0.91 (95% confidence interval 0.88–0.95)/10% higher, P¼0.0001]
and after [0.90 (0.87–0.93), P¼0.0001] adjustment. Adjustment for future CD4þ
changes revealed that the association was explained by poorer CD4þ cell counts in
those with lower %IC. In total 8730 participants under follow-up for more than 1 year
initiated ART of whom 237 (2.7%) died. Higher values of %IC prior to ART initiation
were associated with a reduced risk of mortality before [0.29 (0.17–0.47)/10%,
P¼0.0001] and after [0.36 (0.21–0.61)/10%, P¼0.0002] adjustment; the association
was again explained by poorer post-ART CD4þ/ viral load in those with lower pre-ART
%IC.
Conclusions: Higher levels of engagement in-care are associated with reduced
mortality at all stages of infection, including in those who initiate ART.
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654 AIDS 2017, Vol 31 No 5living with HIVare aware that they are HIV positive, have
linked into care, and have sustained engagement with
care thereafter.
Unpublished data from London HIV clinics indicate that
outpatient nonattendance rates can be as high as 25% (Iain
Reeves, personal communication). Poorer health out-
comes, including failure to suppress HIV viraemia,
increased drug resistance and suboptimal CD4þ cell
count responses, are reported among people living with
HIV who engage poorly with care [3–8]. In the United
Kingdom, missed outpatient appointments have signifi-
cant resource implications [9], and the importance of
continuity of care for reducing costs has been recognized
in several disease areas [10–12]. In the HIV setting,
retaining HIV-positive persons in care may also reduce
new infections, treatment costs, and deaths [13,14].
To explore patterns of engagement in HIV care, it is
essential to adopt a valid and reliable measure, and yet
there is no gold standard measure of engagement in HIV
outpatient care. Researchers have assessed retention in
care in several ways, with definitions commonly based on
the quality indicators proposed by the US Health
Resources and Services Administration HIV/AIDS
Bureau (HRSA HAB), the US Institute of Medicine
(IOM), or the US Department of Health and Human
Services (DHHS) [6,15,16]. These measures have their
own strengths and weaknesses [17], but none of them take
into account the fact that frequency of attendance is
related to changes in ARTand health status and may also
be affected by external forces or changes in clinic policy.
In the United Kingdom, for example, British HIV
Association (BHIVA) guidelines from 2011 indicated that
HIV-positive persons should be seen within 2–4 weeks of
starting ARTand every 3–6 months thereafter for routine
monitoring if they were considered ‘stable’ [18]; recently
updated guidelines suggest that monitoring frequency can
now be reduced to 6 monthly for those on ART with
stable viral suppression [19].
The REACH study (Exploring patterns of Retention and
Engagement Across specialised Care services for HIV
patients in the United Kingdom) set out to develop a
dynamic measure of engagement in-care that would be
sensitive to changes in an individual’s status over time
[20]. Using this measure, we demonstrated that
individuals were deemed to be in-care for 83.9% of
the total follow-up time. To date, however, we have not
investigated whether this measure is able to identify a
group of individuals at high risk of clinical progression.
One of the main limitations of analyses that investigate
associations between engagement in-care and clinical
outcomes is the potential for reverse causality whereby
those who are sickest may attend for care more frequently
as their health deteriorates, thus creating an artificial
association between higher levels of engagement and an
increased risk of clinical progression. Thus, the objectiveof the present analysis was to use data from the UK
Collaborative HIV Cohort (UK CHIC) study to
investigate associations between our measure of engage-
ment in-care and mortality, while reducing any potential
impact of reverse causality.Methods
The UK CHIC Study was initiated in 2001 and collates
routine data on HIV-positive persons attending many of
the UK’s largest HIV clinical centres. The project was
approved by a Multicentre Research Ethics Committee
and local ethics committees. HIV-positive individuals are
included in the study provided they have attended one of
the collaborating centres at any time since 1 January 1996
and are aged at least 16 years [21]. The data set used for the
present study is based on data submitted from 19 clinics
with data collection up to 31 December 2012. The work
was conducted as part of the National Institute for Health
Research Health Protection Research Unit (NIHR
HPRU) in Blood-Borne and Sexually Transmitted
Infections (UCL in collaboration with London School
of Hygiene and Tropical Medicine), a partnership with
Public Health England. TheUKCHIC records are linked
anonymously to mortality data collected as part of
national surveillance programmes conducted by Public
Health England.
Our measure of engagement in-care has been described
[20]. In brief, in the absence of complete data on clinic
attendances, we used CD4þ cell counts, viral loads,
haemoglobin measures and ART start/switch dates as
markers of clinic attendance. As people often return for
repeat laboratory tests over a short period of time to
confirm unexpected findings, resulting in clusters of
attendances around a single ‘index’ date, we grouped
attendances into ‘care episodes’, defined as months where
at least one visit occurred. For each care episode, we
established the lowest CD4þ cell count measured in that
month (and the change from the previous value), the
highest HIV viral load, the person’s ART status and
identified whether the person had received a recent HIV
diagnosis, and used this information to establish the likely
month of the next scheduled visit using our algorithm.
The date of the next observed care visit determined
whether the person had attended at any time in the period
leading up to the expected date. If so, the person-months
up to the observed visit were all classified as being in-care;
if not, the person-months up to the date of the expected
visit were classified as in-care (as the person’s attendance
had not, at that point, deviated from what was expected)
whereas the subsequent person-months until the
observed visit were classified as out-of-care. Each
person-month between consecutive visits was thus
classified as being in or out-of-care.
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Table 1. Characteristics of patients included in the two sets of
analyses.
All study
participants
at baseline
Study
participants
at ART1 start
N 44432 8730
Sex (%) Men 72.2 78.2
Women 27.8 21.8
Age (years) Median (IQR) 36 (30, 42) 37 (32, 43)
Exposure (%) MSM 50.5 62.3
Heterosexual 39.1 31.1
IDU 3.0 2.9
Other/unknown 7.4 3.7
Ethnic group (%) White 53.3 63.4
Black African 28.9 20.9
Other 8.7 8.9
Unknown 9.2 6.8
CD4þ cell count
(cells/ml)
Median (IQR) 355 (214, 520) 280 (202, 368)
ART, antiretroviral therapy; IQR, interquartile range.We included all people who attended a participating UK
CHIC clinic on at least one occasion between 1 January
2000 and 31 December 2012. We used Cox models to
assess the association between mortality and the
cumulative proportion of months a person had been
in-care (%IC) and the cumulative proportion of months a
person was in-care prior to ART.
For analyses of the association within the full cohort,
person follow-up started at study entry and ended at the
earliest of death or six months after the person’s last clinic
attendance. Each person’s total follow-up period was split
into consecutive monthly intervals and the cumulative
proportion of previous months she/he had been in-care at
the start of each month was calculated (%IC). In this way,
we were able to include %IC as a continuous time-
updated covariate in regression models. To reduce the
potential for our analyses to be affected by reverse
causality, all measures of %IC were lagged by 12 months
to separate the assessment of engagement and the
outcome by a period of 1 year. Thus, our estimated
relative hazard for %IC will describe the relationship
between %IC and clinical events that occur at least 1 year
into the future. Note that this approach will necessarily
restrict analyses to those who had attended clinic for more
than 1 year. In our primary analyses we adjusted for the
demographic factors: age, year, sex, mode of HIV
acquisition and ethnic group (fixed covariates). This was
followed by additional adjustment for receipt of ARTas a
binary time-updated covariate. We next adjusted for the
latest CD4þ cell count, as a continuous time-updated
covariate and lagged by 12 months, to investigate whether
any association seen with %IC was explained by the fact
that those with the lowest %IC values already had poorer
CD4þ cell counts at the time of assessment of
engagement. Finally, we adjusted for the unlagged values
of CD4þ to explore whether any residual association
between %IC and clinical outcomes was mediated by
lower CD4þ cell counts over the following 12 months.
We did not adjust for the latest viral load given the
expected collinearity between this and our ART variable.
For analyses of the subgroup of patients who started ART,
we calculated the %IC prior to ART in the subset of
people who initiated ART and who had been under
follow-up at the clinic for at least a year prior to ART
start. Pre-ART %IC was stratified into six groups (<50%,
50–69.9%, 70–79.9%, 80–89.9%, 90–99.9%, and 100%)
which were chosen for ease of clinical interpretation and
to ensure that each group was of sufficient size to permit
robust analyses. Cox models then considered the
association between pre-ART %IC (as a fixed baseline
covariate) and mortality after ART initiation; follow-up
started at ART initiation and ended at the earliest of
6 months after the person’s last visit or death. We first
adjusted for age, year, sex, mode of HIV acquisition and
ethnic group, then type of ART received [protease
inhibitor based, NNRTI (nonnucleoside reversetranscriptase inhibitor) based, other regimen (including
those on both a protease inhibitor andNNRTI)], then the
CD4þ cell count and viral load at ART start (fixed
covariates) and then finally the latest CD4þ cell count and
viral load (as time-updated covariates) measured after
ART start. As before, these latter analyses investigate
whether any associations between pre-ART %IC and
post-ART mortality can be explained by poorer CD4þ/
viral load responses on ART. Note that as we considered
pre-ART %IC and outcome post-ART, then reverse
causality is unlikely to be of major concern in this analysis.Results
A total of 44 432 UKCHIC participants were included in
the initial analysis (Table 1).Women represented 27.8% of
the sample. Half were white (53.3%), one third were black
African (28.9%), 8.7% were of other ethnicity, and 9.2%
had unknown ethnicity. Around half had acquired HIV
through sex between men (50.5%), with 39.1% acquiring
HIV through sex between men and women, 3.0%
through injection drug use and the remaining 7.4%
through other or unknown routes. The median age at
entry into the study was 36 years (interquartile range
(IQR) 30–42] and the median date of follow-up start was
December 2004 [range January 2000–October 2012).
The median CD4þ cell count at start of follow-up was
355 (IQR 214–520) cells/ml.
Over a median follow-up of 5.5 (IQR 2.0, 10.0) years,
6685 (15.1%) people developed a new AIDS event and
2279 (5.1%) died. Table 2 shows the association between
engagement in-care and mortality, first without adjust-
ment, then after performing an adjusted analysis. The
estimate of the relative hazard after adjustment for fixed
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Table 2. Results from unadjusted and adjusted Cox regression
analyses of associations between%IC andmortality: all patients, and
patients starting antiretroviral therapy.
Mortality
i) All patients RH (95% CI)/10%
higher %IC
Total number (%) deaths 2279 (5.1)
Adjustment for:
None 0.91 (0.88, 0.95)
Fixed covariates 0.91 (0.88, 0.95)
þReceipt of ART (yes/no) 0.90 (0.87, 0.93)
þLatest CD4þ cell count (lagged) 0.96 (0.92, 1.00)
þLatest CD4þ cell count (unlagged) 1.00 (0.96, 1.04)
ii) Patients starting ART RH (95% CI)/10%
higher %IC
Total number (%) deaths 237 (2.7%)
Adjustment for:
None 0.29 (0.18, 0.47)
Fixed covariates 0.31 (0.18, 0.51)
þBaseline ART regimena 0.32 (0.19, 0.53)
þBaseline CD4þ cell count and viral load 0.36 (0.21, 0.61)
þLatest CD4þ cell count and viral load 0.74 (0.42, 1.30)
ART, antiretroviral therapy; CI, confidence interval; RH, relative
hazard.
aProtease inhibitor based, nonnucleoside reverse transcriptase inhibi-
tor based or other.covariates and ART status demonstrates that higher
engagement in-care is associated with less rapid
progression to death when this is considered at least 1
year into the future. Adjustment for the lagged CD4þ cell
count resulted in an attenuation of the association
between %IC and mortality, demonstrating that a
proportion of the association seen can be explained by
the fact that those with lower %IC values also have lower
CD4þ cell counts. Additional adjustment for the
unlagged CD4þ cell counts led to further attenuation
of the estimate towards 1, suggesting that in addition to
poorer CD4þ cell counts at the time of %IC assessment,
those with lower %IC values also maintained lower CD4þ
cell counts over the subsequent 12-month period.
A total of 8730 individuals had been under follow-up at a
participating clinic before starting ART (Table 1).
Compared with the wider population group, thoseTable 3. Associations between preantiretroviral therapy engagement in-ca
therapy.
n (%) of group Men MSM
%months IC prior to ART % % %
<50% 1282 (14.7) 73.1 46.2
50–70% 1239 (14.2) 76.0 59.5
70–80% 1014 (11.6) 77.7 62.8
80–90% 1591 (18.2) 80.1 65.6
90–99% 2092 (24.0) 79.3 66.4
100% 1512 (17.3) 81.0 68.6
ART, antiretroviral therapy; IC, in-care; MSM, men who have sex with me
inhibitor.starting ARTwere more likely to be men, were slightly
older, more likely to have acquired HIV through sex
between men, of white ethnicity and had a lower CD4þ
cell count.
At the time of starting ART, the median %IC was 85.7%
(range 3.3–100.0%, IQR 65.5–95.7%); %IC was <50%,
50–70%, 70–80%, 80–90%, 90–99%, and 100% in 1282
(14.7%), 1239 (14.2%), 1014 (11.6%), 1591 (18.2%),
2092 (24.0%), and 1512 (17.3%), respectively. Table 3
shows associations between the pre-ART%IC and several
selected demographic and clinical characteristics. Men
were more likely than women to have spent a greater
proportion of time in-care before starting ART. Other
factors associated with a higher proportion of time spent
in-care were HIV acquisition through sex between men,
white ethnicity, a higher CD4þ cell count at start of ART,
and initiation of ARTwith an NNRTI-based regimen.
Over a total post-ART follow-up period of 4.3 (IQR 2.1,
6.8) years, 237 (2.7%) people who started ART died.
Table 2 shows the association between pre-ART%IC and
post-ART mortality, after progressively adjusting for
covariates as before. As in the previous analyses, the strong
association between pre-ART %IC and post-ART
mortality that was apparent in unadjusted analyses and
analyses that control for the baseline covariates was
substantially attenuated towards 1 after further adjustment
for post-ART CD4þ cell count and viral load profiles.Discussion
Using a flexible approach to measuring engagement in-
care that can be adapted to the changing health status of
the individual and to local clinic policies, we have
demonstrated that higher levels of engagement in HIV
care are associated with reduced mortality at all stages of
infection, both in individuals who are receiving ARTand
those who are not. Our findings suggest that this
association is largely explained by poorer CD4þ cellre and selected demographic/clinical factors at start of antiretroviral
White
Regimen
CD4þ (cells/ml) Median
PI NNRTI
% % %
53.5 250 32.1 60.8
60.9 259 25.3 66.4
62.1 280 25.5 67.5
64.9 283 26.2 67.1
65.6 290 23.0 68.6
70.3 299 21.4 70.0
n; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease
Engagement in-care and mortality Sabin et al. 657count profiles in those with suboptimal engagement
in-care.
Definitions of engagement in-care
Although the importance of a high rate of engagement is
well recognised, definitions vary widely between studies
[22].Within the largely North American literature on the
topic, studies have predominantly used one of the
measures utilized by the US DHHS/HRSA HAB, the
IOM or some modification, all of which assess ‘visit
constancy’ over a period of time. For example, the
DHHS/HRSA HAB indicator defines individuals as
being engaged in-care if they have at least one visit in each
of four consecutive 6-month periods, with visits separated
by more than 60 days [5,17,23–25]. The IOM core
indicator classifies individuals as engaged in-care if they
have at least two visits in a 12-month period, where each
visit is separated by more than 90 days [7,16,17,23,
25–28], although adaptations that require only 60 days of
separation are also used [29,30]. Other measures of visit
constancy consider the proportion of a set number of
consecutive time intervals in which patients attend at least
one scheduled appointment [17,26,27,31] or consider a
patient to be engaged in-care if there is no gap in care
more than 6 months [17,26,27,32].
Although measures of visit constancy provide infor-
mation on visits that are kept, they provide little
information on missed visits. Measures of ‘visit adher-
ence’ have therefore also been proposed that classify
individuals according to the number or proportion of
scheduled visits that have been missed over a period
[26,31]. Collection of data on unscheduled missed visits
may, however, be challenging for many clinics, particu-
larly if visits are not recorded as ‘missed’ if they are
rescheduled in advance. Such measures may also be
difficult to implement at a region-wide level or in large
collaborative studies where computer systems may vary.
For pragmatic reasons, therefore, simpler measures of
engagement in-care are often preferred [33–38].
This variation between studies introduces complexity
into any comparison of rates of engagement in different
settings. Mugavero [26] demonstrated considerable
variability between six measures of retention in terms
of the proportion of patients who were considered as
retained in-care. Although each measure was strongly
correlated with viral load suppression, the correlation
between the various measures of retention was as low
as 0.16.
Associations with clinical and virological
outcomes
Several studies have described the association between
engagement in-care and clinical and virological out-
comes. In the South Carolina, enhanced HIV/AIDS
Reporting System (eHARS) surveillance database [5],
mean decrease in viral load and increase in CD4þ cellcount were both greater in those with optimal retention
in-care, and associations with poorer engagement in-care
and mortality have been reported by several groups
[5,6,39]. In a study from the Centers for AIDS Research
(CEFAR) Network of Integrated Clinical Systems
(CNICS) [23], failure to achieve the IOM and DHHS
indicators was associated with increased mortality; among
those classified as retained in-care by either indicator,
however, having more than two missed visits was also
associated with an additional increase in mortality risk.
The authors noted that lifestyle or behavioural factors that
may have increased the risk of a person missing a clinic
appointment may also have been associated with an
increased risk of mortality. Findings from the ALIVE
study [32], in which a significant association between
reporting no HIV care visit in the past 6 months and
virological failure was lost after adjustment for factors that
included predictors of lapses in care, would support the
concern that reported associations between engagement
in-care and virological suppression may not necessarily be
causal. Findings of a stronger association between
retention in-care and viral suppression among those with
lower CD4þ cell counts and in younger adults [17,27],
raise the interesting prospect that measures of engagement
in-care should be interpreted in light of other individual-
level characteristics.
Limitations of current measures of engagement
Several limitations of the currently used measures of
engagement in-care have been noted [25]. First, although
most approaches generally consider engagement in a
cross-sectional manner, engagement in-care is an evol-
ving process, with individuals often moving in or out of
care as their personal circumstances and health change.
For example, Colasanti reported that while 12-month
retention and virological suppression rates at the
Infectious Disease Program of the Grady Health System
in Atlanta were both high, only 49% of participants had
maintained continued retention and only 39% continu-
ous virological suppression for 36 months [15]. Further-
more, clinic monitoring policies are also changing, in
response to improved outcomes on ART and increasing
patient numbers. Our proposed approach to defining
engagement in-care reflects such changes at both an
individual and clinic level.
Second, associations between calendar year and engage-
ment in-care are often subject to bias. It may be difficult
to differentiate between permanent loss to follow-up and
transient interruptions in-care among patients followed in
more recent periods because of insufficient follow-up
[40], and though it may be tempting to attribute
improvements in engagement in-care rates to the
increased use of interventions to reduce disengagement,
apparent improvements may simply reflect the fact that
those who are diagnosed and/or start ART in later
follow-up periods may have had less opportunity to miss a
clinic appointment.
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consideration of the fact that individuals may seek care
from other providers. The implications of such individ-
uals for the overall care cascade are unclear – in Southern
Alberta, patients who left the HIV care program but who
returned at a later date had deterioration in both CD4þ
cell counts and new AIDS events compared with those
who had never left the program, in whom CD4þ cell
counts increased [41]. In contrast, transfers into the care
centre from outside the area had greater engagement in-
care than local patients [33]. At a population level, the
choice of denominator can be crucial for estimates:
engagement in-care from King County, Washington,
ranged from 66–81% depending on the definition of the
denominator population [42].
Finally, although engagement in-care would ideally be
measured through face-to-face clinical encounters, many
studies have used laboratory markers of disease pro-
gression (e.g. CD4þ cell counts and viral loads) as
surrogates for clinic encounters [43–47]. Reflecting the
fact that the UK CHIC study is a large study which uses
routinely collected electronic data only, our proposed
algorithm also uses a combination of laboratory and
clinical data as a surrogate. The potential for this approach
to underestimate engagement in-care has been assessed,
with studies generally reporting that while laboratory
markers are able to discriminate between persons retained
and not retained in-care, absolute engagement rates are
often lower when estimates are based on laboratory data
[44–46]. In contrast, in a small study of 99 newly
diagnosed patients in Louisiana, Halperin [28] reported
that the use of laboratory markers as a proxy for clinical
visits tended to overestimate currently accepted
definitions of engagement in-care.
Strengths and limitations of the present study
Our analyses benefit from a large, prospectively compiled,
clinical data set with longitudinal data on CD4þ cell
counts, viral loads, and ART use. By separating our
assessment of engagement from clinical outcomes by 12
months, we were also able to reduce the impact of reverse
causality, whereby individuals who are sicker may attend
for care more frequently than those who are well
(although we recognize that some residual reverse
causality bias may remain). However, some limitations
of our study should be noted. By taking this approach, we
are unable to assess the impact of engagement in care on
outcomes within the first 12 months of follow-up for an
individual, and our analyses may not be generalizable to
those under care for periods of less than 12 months. We
attempted to investigate whether the association seen
could be mediated through poorer CD4þ profiles both at
the time of assessment of engagement in-care as well as
over the subsequent period. However, these analyses will
be incomplete if follow-up CD4þ cell counts and viral
loads are more likely to be missing in those with poorer
engagement in-care. Although our algorithm can beadapted to other settings (e.g. resource-limited settings
where laboratory monitoring is less frequent), general-
izability to those settings is uncertain. Finally, we
recognize that our algorithm does not capture additional
information that might modify a clinician’s decision about
the timing of the next visit (e.g. psychosocial factors).
Summary
In summary, we have shown that, among patients
attending for care for at least a year, a combination of
routinely collected clinical and laboratory data is able to
identify, through engagement patterns, individuals at
increased risk of subsequent mortality both before and
after starting ART.Acknowledgements
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